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Saccharomyces cerevisiaeWe previously identiﬁed the Arabidopsis thaliana-derived decapeptide OSIP108, which increases tolerance of
plants and yeast cells to oxidative stress. As excess copper (Cu) is known to induce oxidative stress and apoptosis,
and is characteristic for the human pathology Wilson disease, we investigated the effect of OSIP108 on Cu-
induced toxicity in yeast. We found that OSIP108 increased yeast viability in the presence of toxic Cu concentra-
tions, and decreased the prevalence of Cu-induced apoptotic markers. Next, we translated these results to the
human hepatoma HepG2 cell line, demonstrating anti-apoptotic activity of OSIP108 in this cell line. In addition,
we found that OSIP108 did not affect intracellular Cu levels in HepG2 cells, but preserved HepG2 mitochondrial
ultrastructure. As Cu is known to induce acid sphingomyelinase activity of HepG2 cells, we performed a
sphingolipidomic analysis of OSIP108-treated HepG2 cells. We demonstrated that OSIP108 decreased the levels
of several sphingoid bases and ceramide species. Moreover, exogenous addition of the sphingoid base
dihydrosphingosine abolished the protective effect of OSIP108 against Cu-induced cell death in yeast. These
ﬁndings indicate thepotential of OSIP108 to prevent Cu-induced apoptosis, possibly via its effects on sphingolipid
homeostasis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Using Tiling Array technology we recently identiﬁed a decapeptide,
termed OSIP108, in the plant Arabidopsis thaliana upon treatment with
the herbicide paraquat (PQ) [1]. PQ induces reactive oxygen species
(ROS) [2]. We found that OSIP108 increases tolerance of plant cells to
oxidative stress agents like PQ.Moreover, a signiﬁcantly increased toler-
ance to H2O2 was also demonstrated in the model yeast Saccharomycesen species; Cu, copper; WD,
h, dihydrosphingosine; MTT,
omide; DHE, dihydroethidium;
end labeling; H2DCFDA, 2′,7′-
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sine-1-phosphate; dhSph-1P,
ramide; Cer, ceramide; SM,
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l.: +32 16329682; fax: +32
.A. Cammue).cerevisiae by either heterologous expression of the OSIP108-encoding
gene or after exogenous application of OSIP108 to H2O2-treated yeast
[13]. Hence, OSIP108 seems to protect various cell types against
oxidative stress inducing agents such as PQ and H2O2.
Excess copper (Cu) was shown to induce oxidative stress and
apoptosis. Copper (Cu), like zinc and iron, is an essential trace element
required for normal cellular functioning. For instance, Cu acts as an essen-
tial co-factor of a variety of enzymes such as cytochrome c oxidase and
Cu,Zn superoxide dismutase [3,4]. However, excess Cu can become
toxic, as in the case of Wilson disease (WD), a human pathology charac-
terized by Cu accumulation in the liver [5] resulting in acute liver failure
or cirrhosis [6]. Reported mechanisms underlying Cu toxicity are related
to mitochondrial dysfunction and damage, since Cu causes (i) a deﬁcien-
cy in themitochondrial respiratory chain at the level of the Cu-dependent
complex IV [7]; (ii) cross-linking of mitochondrial membranous proteins
and subsequent contraction of the membrane [7]; (iii) oxidative stress
[8–11]; and (iv) increased acid sphingomyelinase (aSMase) activity [12].
The latter results in an increased production of ceramide [12], which
has been shown to modulate mitochondrial outer membrane
permeabilization and to induce apoptosis [13,14].
1208 P. Spincemaille et al. / Biochimica et Biophysica Acta 1843 (2014) 1207–1215As ROS are known to induce apoptosis via both intrinsic and extrinsic
apoptotic pathways [15], we investigated in the present study the poten-
tial protective effects of OSIP108 against Cu-induced oxidative stress and
apoptosis. To this end, we studied the effect of OSIP108 on cell survival
and apoptotic levels of either a lower and a higher eukaryote (yeast
and human, respectively) in the presence of toxic Cu concentrations.
All data point to the anti-apoptotic potential of OSIP108 via its effect on
sphingolipid homeostasis.
2. Materials and methods
2.1. Materials, yeast strains and cell lines
The yeast strains used in this study are S. cerevisiaewild type yeast
strain BY4741 (WT) and Δyca1 deletion mutant (Euroscarf, Germany)
and were cultured in SC (0.77 g/L complete amino acid supplement
mixture (CSM) (Bio 101 Systems); 6.7 g/L yeast nitrogen base without
amino acids (YNB); 20 g/L glucose) medium. HepG2, human
hepatoblastoma cells were obtained from ATCC (Rockville, MD, USA)
and grown in Minimal Essential Medium (MEM) supplemented with
10% fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin and
100 μg/mL streptomycin. Copper sulfate (CuSO4) and copper chloride
(CuCl2) (Cu) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
OSIP108 (MLCVLQGLRE, 1161 g/mol) and OSIP3.2D (MSRRMILTQYW,
1484 g/mol) were purchased from Thermo Fisher Scientiﬁc (Ulm,
Germany). Dihydrosphingosine (dhSph) was purchased from Avanti
Polar Lipids, Inc. (Alabama, USA). Solvent for peptides and dhSph was
DMSO.
Protocols involving qRT-PCR analysis of OSIP108 treatedHepG2 cells
are included in the Supplementary data.
2.2. Yeast Cu toxicity experiments in agar
An overnightWT yeast culture in SCwas diluted 50-fold in SC growth
medium containing 0.8% agar, 0.1 mg/mL 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, MO,
USA) and 100 μM Cu. 5 μL of 100% DMSO (vehicle control), 20 mM
OSIP108 or 20 mM OSIP3.2D was spotted onto the plates. After 24 h of
incubation at 30 °C, purple halo diameters, indicative for cell survival,
were evaluated.
2.3. Yeast Cu survival in liquid media
An overnight yeast culture in SC was diluted to OD600 = 2 in fresh
SC and incubated with control (distilled H2O) or 2 mM Cu upon treat-
ment with 2% DMSO (vehicle control) or 100 μM OSIP108. After 4 h in-
cubation (30 °C, 250 rpm) appropriate cell dilutions were plated onto
YPD agar plates. Cell survival was quantiﬁed by determining CFU/mL
as compared to cells receiving no Cu. As for exogenous dhSph addition,
yeast cellswere treated as described above in the presence or absence of
dhSph (5 μg/mL–20 μg/mL).
2.4. Detection of apoptotic markers in yeast
An overnight WT yeast culture in SC was diluted to OD600 = 2 in
fresh SC and incubated with 2 mM Cu in the presence of 2% DMSO
(vehicle control) or 100 μM OSIP108. After 4 h incubation (30 °C,
250 rpm) 5·106 cells were washed twice with PBS and stained with
5 μg/mL dihydroethidium (Molecular Probes) (DHE) or 20 μMCaspACE
FITC-VAD-FMK (Promega Benelux BV) in PBS by incubating at 30 °C for
20 min. To detect DNA fragmentation terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL) assay was performed. Brieﬂy,
following Cu treatment (2 mM) in the presence of vehicle control or
100 μM OSIP108, 4·107 cells were ﬁxed with 70% ethanol for 15 min
at room temperature and cell wall was digestedwith 30 U/mL zymolyase
20T (Seikagaku, Tokyo, Japan) in zymolyase buffer (1 M sorbitol, 1 mMEDTA, 10 mM sodium citrate, pH 5.8) for 15 min at 30 °C. Next, cells
were incubated with permeabilization solution (0.1% Triton X100,
0.1% sodium citrate) for 2 min on ice before incubating the cells with
TUNEL reaction mixture (In Situ Cell Detection Kit, Roche Diagnostics
BelgiumNV, Belgium) according tomanufacturer's description. Following
each staining, samples were washed twice with PBS, and ﬂow cytometry
analysis was performed using BD Inﬂux ﬂow cytometry (BD Biosciences,
New Jersey, NJ, USA). Datawas analyzed using FlowJo software (Tree Star
Inc., Ashland, MA, USA). 20,000 cells/sample were analyzed.
2.5. HepG2 Cu toxicity experiments
HepG2 cells were seeded at 104 cells/well in a 96-well plate inmedi-
um containing 1% DMSO (vehicle control) or OSIP108 (10 μM–100 μM).
Following16h preincubation, cellswere treatedwith 0.75mMCu in the
presence of vehicle control or OSIP108 (10 μM–100 μM) After 48 h
incubation, cell viability was determined by MTT viability staining as
described [16].
2.6. Detection of apoptosis and oxidative stress in HepG2 cells
HepG2 cells were seeded at 106 cells/well in a 6-well plate and incu-
bated overnight in the presence of 1%DMSO (vehicle control) or 100 μM
OSIP108. Next, cellswere incubated for 24hwith 0.5mMCu and vehicle
control or 100 μM OSIP108. Cell culture supernatants and cells were
collected and co-stained with FLUOS-labeled Annexin V (AnnV)
(Roche Diagnostics NV Belgium, Belgium) and propidium iodide (PI)
(Sigma-Aldrich, St. Louis, MO, USA). ROS levels were determined using
2′,7′-dichlorodihydroﬂuorescein diacetate (H2DCFDA; Life Technologies).
Cells were incubated with Cu and the dye for 60 min at 37 °C. DCF
positive, viable cells were recorded. Following staining, cells were
analyzed by ﬂow cytometry (Beckman Coulter Epics XL.MCL) and
data was analyzed by CXP software Version 1.0.
2.7. Cellular Cu binding
Cellular copper determination was performed according to
Cater et al. [17]. Brieﬂy, HepG2 cells were seeded at 106 cells/well
into a 6-well plate and cultured for 12 h in medium containing 1%
DMSO (vehicle control) or 100 μM OSIP108. Next, the medium was re-
placed by fresh medium containing 0.1 mM Cu. After 24 h incubation,
cells were washed with PBS and trypsinized. After centrifugation, dried
cell pellets were dissolved in 65% nitric acid (Suprapure, Merck,
Germany) and incubated overnight at 65 °C. Total amount of Cu was an-
alyzed by atom absorption spectroscopy (Atomic absorption spectropho-
tometer Shimadzu AA6300, Japan) as described [16].
2.8. Electron microscopy
HepG2 cells were seeded at 106 cells/well in a 6-well plate in media
containing 1% DMSO or 100 μM OSIP108. After overnight incubation,
cells were cultured in freshmedium containing 0.75mMCu and vehicle
control or 100 μM OSIP108 respectively. After 16 h incubation, cells
were ﬁxed in 2% glutaraldehyde and 0.5% osmium tetroxide in 0.1 M
PBS, dehydrated with ethanol, and embedded in Epon using standard
procedures as described [18]. Thin sections were cut using an ultrami-
crotome and contrasted with uranyl acetate and lead citrate. Sections
were examined with an EM410 electron microscope (Philips) and
documented digitally (DITABIS).
2.9. Sphingolipidomics on OSIP108-treated HepG2 cells
HepG2 cells were seeded at 105 cells/plate in 60 mm plates and
following 24 h incubation cells were treated with 1% DMSO (vehicle
control) or 100 μM OSIP108 in serum free media. Following 48 h
treatment with OSIP108, cells were washed twice with cold PBS,
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(30:10:60 by vol). Cell extracts were analyzed by reverse phase
high pressure liquid chromatography coupled to electrospray ioniza-
tion and subsequent separation by mass spectrometry. Analysis of
sphingoid bases, ceramides and sphingomyelins was performed on
a Thermo Quantum Ultra mass spectrometer, operating in a multiple
reaction-monitoring positive ionization mode, as described [19].
2.10. Statistical analysis
All values are presented as mean with standard error (SEM). Data
were analyzed by GraphPad Prism 6 software. P b 0.05 was considered
as statistically signiﬁcant.
3. Results and discussion
3.1. OSIP108 increases yeast tolerance to Cu
We previously described the protective effect of the bioactive plant-
derived peptide OSIP108 (MLCVLQGLRE) against oxidative stress in
plant and yeast cells [1]. Since Cu has been shown to induce oxidative
stress and ROS [8–11], we investigated the effect of OSIP108 on the
growth and survival of wild type S. cerevisiae BY4741 (WT) in Cu-
containing media. As negative control, OSIP3.2D, a random 11 amino
acid long peptide (MSRRMILTQYW) was selected from our previous
study, in which in contrast to OSIP108, it failed to increase yeast toler-
ance to H2O2 [13]. To this end, WT yeast was inoculated in solid growth
medium containing a lethal Cu concentration (100 μM) and the viability
dye MTT. OSIP108 (20 mM) and OSIP3.2D (20 mM) were spotted onto
the agar and after 24 h of incubation, purple halos around the spotted
peptides were evaluated, indicative of viable yeast cells via conversion
of the viability dye MTT. We consistently found a purple halo around
the spotted OSIP108 peptide, in contrast to OSIP3.2D and solvent only
(vehicle control) (Fig. 1a). In addition, we evaluated the effect of
OSIP108 on yeast survival in the presence of Cu in liquidmedia by deter-
mining colony forming units (CFU). We observed that 2 mM Cu de-
creased yeast survival to 26 ± 2%, whereas survival of cells receiving
100 μM OSIP108 increased to 40 ± 4% (Fig. 1b). OSIP108 did not affect
yeast survival in the absence of Cu (data not shown). These data indicate
that addition of exogenous OSIP108 increases yeast tolerance to Cu.
3.2. OSIP108 prevents Cu-induced apoptosis of yeast cells
As Cu is known to induce apoptosis of yeast cells [20], we further
assessed whether OSIP108 is characterized by a general anti-apoptotic
activity. To this end, we investigated the prevalence of several apoptoticFig. 1. OSIP108 increases Cu tolerance of yeast cells. (a) WT yeast cells were inoculated in 10
Vehicle control (1), OSIP3.2D (2) or OSIP108 (3) was spotted onto the agar plates. After 24 h
MTT, were evaluated. Bar represents halo diameter. Data are representative of 3 independent
vehicle control or 100 μM OSIP108. Following incubation, cell dilutions were plated onto YPD a
to cells receiving no Cu. Experiments were performed in quadruplicate, with 4 biological repeahallmarks by means of ﬂow cytometry, including production of ROS,
DNA fragmentation and caspase activity in yeast [21] upon Cu treat-
ment. In a ﬁrst step, we assessed the effect of different Cu doses on
yeast cell survival in liquid media and the effect of OSIP108 on yeast
cell survival in the presence of a toxic Cu concentration. In line with
the observations described by Liang and Zhou [20], demonstrating
that Cu induces apoptosis of yeast cells, we found that incubation of
yeast cells with 2mMCu resulted in increased superoxide accumulation
as documented by a signiﬁcantly higher percentage of DHEpositive cells
as compared to cells receiving no Cu (Fig. 2a). By performing TUNEL
assay, we found that Cu treatment increased the amount of ﬂuorescent
yeast cells, indicating that Cu induces DNA fragmentation in yeast
(Fig. 2b). In addition,we investigated the contribution of active caspases
in Cu-induced toxicity in yeast. Caspases are cysteine-aspartic speciﬁc
proteases generally known to play an essential role in apoptosis. Both
caspase-dependent and caspase-independent cell death pathways to
apoptosis have been described in yeast [22]. By staining Cu-treated
yeast cells with a ﬂuorescent analogue of the pan caspase inhibitor
(FITC-VAD-FMK), which binds to active caspases, and subsequent ﬂow
cytometry analysis, we found that Cu increases the amount of yeast
cells with active caspases (Fig. 2c). All these data indicate that Cu in-
duces caspase or caspase-like protease-dependent apoptosis in yeast.
Next, we investigated potential anti-apoptotic activity of OSIP108
using Cu-induced apoptosis in yeast as a model, by assessing the
above apoptosis-related markers in the presence and absence of
OSIP108. We demonstrated that addition of 100 μM OSIP108 to yeast
cells treated with 2 mM Cu decreased the amount of DHE positive
cells (Fig. 2a) as well as the amount of cells with DNA fragmentation
as determined by TUNEL assay (Fig. 2b). Moreover, we found less cells
with active caspases or caspase-like proteases upon incubation with
OSIP108 as compared to vehicle control (Fig. 2c). These data indicate
that OSIP108 reduces all tested hallmarks of Cu-induced apoptosis in
yeast, thereby increasing yeast cell survival in the presence of Cu.
Since our data indicate that active caspases or caspase-like proteases
are involved in Cu-induced apoptosis in yeast, and that OSIP108
decreases the number of cells with caspase or caspase-like activity, we
further investigated the Cu tolerance of Δyca1 yeast cells. The yeast-
like protease Yca1p plays a major role in the caspase-dependent yeast
apoptotic pathway induced by H2O2 [23], acetic acid [24] or valproic
acid [25]. Previous studies by Liang and Zhou [20] and Horowitz et al.
[26] reported no difference in Cu tolerance of WT and Δyca1 yeast,
indicating that Cu-induced apoptosis in yeast does not require a func-
tional metacaspase Yca1p. In line with the literature [20,26], our results
showed no signiﬁcant difference in tolerance to 2 mM Cu of WT and
Δyca1 yeast cells (Supplemental Fig. S1). These data indicate that the
anti-apoptotic effects of OSIP108 on yeast are not mediated by the0 μM Cu-containing growth medium supplemented with agar and the viability dye MTT.
incubation, purple halos indicative for cell survival due to conversion of the viability dye
experiments. (b) WT yeast cells were incubated for 4 h with 2 mM Cu in the presence of
gar plates and survival was quantiﬁed by determining colony forming units as compared
ts (**P b 0.01; Student's t-test).
Fig. 2.OSIP108 decreases Cu-induced apoptotic hallmarks in yeast.WT yeastwas incubated
for 4 h with 100 μM vehicle control (black bars) or 100 μM OSIP108 (gray bars) in the
presence or absence of Cu. Following incubation, cells were stained with DHE (a) to deter-
mine superoxideproduction, TUNEL assay, (b) to detect DNA fragmentation, or FITC-labeled
VAD-FMK and (c) to determine active caspases or caspase-like proteases. Samples were
analyzed by ﬂow cytometry. Assays were performed in at least 3 biological repeats
(*P b 0.05; **P b 0.01; ***P b 0.001; Student's t-test).
Fig. 3. OSIP108 reduces Cu sensitivity of mammalian cells. (a) HepG2 cells were preincu-
bated with vehicle control (V.c.) or OSIP108 (10 μM–100 μM) prior to further incubation
with V.c. or OSIP108 (10 μM–100 μM) and 0.75 mM Cu. Cell viability was determined by
MTT staining. Mean and SEM of three experiments are shown (*P b 0.05; ***P b 0.001;
ANOVA test using Tukey's correction). HepG2 cells were preincubated overnight with
vehicle control or 100 μMOSIP108 prior to co-incubation in 0.5mMCu and vehicle control
(black bars) or 100 μM OSIP108 (gray bars) for 24 h. Following incubation, cells were
stained with (b) H2DCFDA or (c) FLUOS-labeled AnnV and samples were analyzed by
ﬂow cytometry. Mean and SEM of 3 biological repeats are shown (*P b 0.05; **P b 0.01;
***P b 0.001; Student's t-test).
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3.3. OSIP108 increases Cu tolerance of the human hepatomaHepG2 cell line
Given the conservation of copper homeostasis regulation [27–29]
and apoptosis [21,30] between yeast and human, we translated our
data obtained with yeast to a higher eukaryotic HepG2 cell line. We
found that incubating HepG2 cells in the presence of 0.75 mM Cu
decreased cell viability of cells receiving vehicle control or 100 μM
OSIP108 to 4.75 ± 1.49% and 5 ± 0.59% respectively, while
preincubation with 100 μM OSIP108 prior to simultaneous addi-
tion of 100 μM OSIP108 and 0.75 mM Cu increased cell viability
to 32.75 ± 5.54% (data not shown). In addition, titration of the
OSIP108 concentration (10 μM–100 μM) indicated a dose–response re-
lationshipwith regard to increase inHepG2 cell viability in the presence
0.75 mM Cu (Fig. 3a). In contrast to yeast cells, in which OSIP108 also
exerts anti-apoptotic activity without OSIP108 pretreatment of thecells, we found that preincubation of HepG2 cells with OSIP108 is nec-
essary prior to Cu addition. This could indicate that the anti-apoptotic
activity of OSIP108 depends e.g. on the individual copper sensitivity of
the cell type, growth characteristics and/or kinetics of OSIP108 uptake.
This is, however, not the ﬁrst observation of a preincubation step with
a compound in order to observe anti-apoptotic effects. For instance,
Guo and coworkers observed that preincubation of PC12 cells with the
antioxidant Ac-cel prior to H2O2 addition decreased H2O2-induced
cytotoxicity and prevalence of apoptotic markers [31] while Lim and
coworkers found that preincubation of Friedrich's ataxia patient ﬁbro-
blasts with lipophilic iron chelators prevented H2O2-induced cytotoxic-
ity [32]. Even the protective effects of the anti-apoptotic peptide
humanin (HN) against amyloid-β 1–42 (aβ 1–42)-induced apoptosis
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simultaneous addition of HN and aβ 1–42 [33].3.4. OSIP108prevents Cu-inducedoxidative stress andapoptosis inHepG2cells
Since excess Cu has been shown earlier to induce oxidative stress
[8–11] and apoptosis in hepatocytes [12,34] we further evaluated
whether the observed protectant effect of OSIP108 on Cu-treated
HepG2 cells could be related to its anti-apoptotic activity, similar to
our experiments in yeast using ﬂow cytometry analysis of apoptotic
markers. OSIP108 treatment signiﬁcantly reduced Cu-induced ROS
levels in HepG2 cells (Fig. 3b). We found that a signiﬁcantly lower
percentage of HepG2 cells was AnnV-positive after 100 μM OSIP108
treatment as compared to vehicle-treated cells treated in the presence
of 0.5 mM Cu (Fig. 3c). Necrosis was also slightly reduced by OSIP108
treatment as determined by PI staining although less than 1% PI positive
cells were observed (Supplemental Fig. S2). Noteworthy here is our
observation that Cu-induced alterations of cell morphology, including
cell rounding and shrinkage, were reversed following OSIP108
treatment, as observed by ﬂow cytometry analysis of cell size and
granularity (data not shown). In general these data indicate that
OSIP108 also prevents Cu-induced ROS formation and apoptosis of
hepatocytes, similar to its effect on yeast cells.Fig. 4. OSIP108 does not affect intracellular Cu levels and preserves mitochondrial
integrity. (a) Intracellular Cu levels of 0.1 mM Cu-treated HepG2 cells pretreated
with vehicle control or 100 μM OSIP108 were determined by atom absorption
spectroscopy. Intracellular Cu levels were not signiﬁcantly different (n.s.). Mean
and SEM of 3 biological repeats are shown (P N 0.05, Student's t-test). b) Electron
microscopy of HepG2 cells grown in 0.75 mM Cu-containing medium in the presence
or absence of 100 μM OSIP108. Regular shaped mitochondria (↓), elongated mito-
chondria with condensation and increased matrix density (←) and vacuolization
(↑) are denoted by arrows. Bar represents 0.2 μm. Data representative for 3 biological
repeats.3.5. OSIP108 does not modulate intracellular Cu levels but preserves
mitochondrial ultrastructure
One of the general cellular Cu detoxiﬁcation mechanisms is Cu se-
questration or chelation to limit its toxicity by cysteine-rich
metallothioneins, peptides or proteins, which harbor cysteinyl sulfurs
that can act as ligands for Cu [35,36]. To gain more insight into the
mode of action of OSIP108, and to exclude extracellular Cu chelation
by the cysteine in OSIP108, we determined the Cu-content of Cu-
treated HepG2 cells in the presence of OSIP108. Atom absorbance spec-
troscopy analysis of HepG2 cells treated with 0.1 mM Cu showed that
100 μM OSIP108-treated cells were loaded with equal amounts of Cu
as compared to the vehicle control suggesting that the peptide does
not affect the Cu uptake (Fig. 4a) as is known for D-penicillamine, a
Cu-chelating drug used to treat WD patients [37]. In addition, gene ex-
pression analysis of a subset of genes related to Cu transport and oxida-
tive stress such as SOD1, encoding the superoxide dismutase 1 protein
involved in detoxiﬁcation of the ROS superoxide, and GSS, encoding
the glutathione synthetase protein which catalyzes the second step in
the synthesis of the antioxidant glutathione, indicated that OSIP108
does not affect major mechanisms of Cu homeostasis in eukaryotic
cells (Supplemental Fig. S3). Furthermore, electron microscopy experi-
ments were used to assess mitochondrial damage upon Cu treatment.
We observed that 0.75mMCu-treatedmitochondria were pleomorphic
and had increasedmatrix density and frequently found elongated forms
of mitochondria, similar to mitochondria of hepatocytes during the
course of WD [7,38] (Fig. 4b middle panel). We also we observed a
high grade of vacuolization indicating advanced damage by Cu [38].
OSIP108 treatment in the presence of Cu resulted in regular shaped mi-
tochondriawith normal cristae structures (Fig. 4b bottompanel) similar
to cells receiving no Cu (Fig. 4b top panel). Vacuolization was absent in
OSIP108 treated Cu-exposed cells, suggesting that the peptide has a
high cytoprotective effect including preservation of mitochondrial ul-
trastructure. These data indicate that OSIP108 protects HepG2 cells
against Cu-induced mitochondrial damage without chelating extracel-
lular Cu or affecting Cu uptake. Of note, the cytoprotective effects of
OSIP108 were observed at a wide range of Cu concentrations in the dif-
ferent assays (data not shown). However, since the rate of necrotic cells
limited statistical analysis, a lower Cu concentration was assessed in
some of the experiments.
Fig. 5.OSIP108 affects sphingolipid homeostasis inHepG2 cells. (a)Major pathways involved in ceramide generation. HepG2 cellswere treatedwith vehicle control (black bars) or 100 μM
OSIP108 (gray bars) for 48 h. Next, cells were harvested and sphingolipidswere extracted. (b) Sphingoid bases, (c) dihydroceramide species, (d) ceramide species and (e) sphingomyelin
species were identiﬁed by tandem mass spectrometry. Mean and SEM of three biological repeats are shown (*P b 0.05; **P b 0.01; Student's t-test).
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Fig. 6. Exogenously added dhSph prevents the protective effect of OSIP108. WT yeast cells
were treated with vehicle control (black bars), 100 μM OSIP108 (vertical dashed bars),
5 μg/mL dhSph (gray bars), 20 μg/mL dhSph (white bars), 5 μg/mL dhSph + 100 μM
OSIP108 (horizontal dashed bars) or 20 μg/mL dhSph + 100 μM OSIP108 (chessboard
pattern bars) in the presence or absence of 2 mM Cu. Following 4 h incubation, survival
was quantiﬁed by determining CFU/mL as compared to vehicle control receiving no Cu.
Mean and SEM of 3 biological repeats are shown (**P b 0.01; ***P b 0.001; ANOVA test
using Tukey's correction).
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Several pathways are known to be involved in the generation of
ceramides as summarized in Fig. 5a. Ceramide can be biosynthesized
de novo or via the salvage pathway. The salvage pathway produces
ceramide from hydrolysis of sphingomyelin. Subsequently, the cer-
amide produced by either the de novo or salvage pathways can be
converted to sphingosine (Sph) which is then phosphorylated to
produce sphingosine-1-phosphate (Sph-1-P). Sph-1-P is then
cleaved into phosphoethanolamine and fatty acids which represent
the only exit route from the sphingolipid pathway [39]. Ceramides
are known to induce apoptosis [15], by altering mitochondrial func-
tion [13,14,40–42], and are associated with the generation of ROS
[43–45]. Given the observed anti-apoptotic effect of OSIP108 in
yeast and human cells, and its protective effect on Cu-induced mito-
chondrial damage, involving acid sphingomyelinase activation [12]
we reasoned that OSIP108 might affect sphingolipid homeostasis
in HepG2 cells. Based on the observation that preincubation of
HepG2 cells with OSIP108 prior to Cu addition was necessary to in-
crease HepG2 viability, we chose to perform sphingolipidomics on
OSIP108-treated HepG2 cells in the absence of Cu. Sphingolipidomic
analysis showed that OSIP108 treatment (100 μM) decreased
levels of several sphingolipid species from the two ceramide
generating pathways. We found that OSIP108 decreased Sph, Sph-
1P and dihydrosphingosine-1-phosphate (dhSph-1-P) levels
(Fig. 5b), as well as several dihydroceramide (dhCer) (C12, C14)
species (Fig. 5c), ceramide (Cer) (C18:1 and C26) (Fig. 5d) and
sphingomyelin (SM) species (C14, C18, C20:1, C24) (Fig. 5e).
Although dhSph levels were not signiﬁcantly affected by OSIP108
treatment (P = 0.0518; Student's t-test), these data suggest an
effect of OSIP108 on 3-ketodihydrosphingosine reductase activity,
which catalyzes the reduction of 3-ketodihydrosphingosine to
dhSph.
3.7. Exogenous dhSph addition abrogates the protective effect of OSIP108 on
Cu-induced toxicity in yeast cells
Given our observation that OSIP108 affects sphingolipid homeostasis
in HepG2 cells, we further investigated a putative role of sphingolipids in
preventing Cu-induced cell death. Sphingolipid generating pathways are
well conserved between yeast and mammalian cells and both produce
dhSph as the second intermediate in de novo sphingolipid biosynthesis
[46]. We chose to validate the sphingolipidomics data in yeast by inves-
tigating the effect of exogenous addition of dhSph in our yeast model for
Cu-induced cell death, in the presence or absence of OSIP108, as OSIP108
apparently downregulates all sphingoid bases and sphingolipids inter-
mediates starting from dhSph. dhSph is efﬁciently taken up and used
in the sphingolipid metabolism in yeast upon exogenous addition
[47–50]. To this end, WT yeast cells were incubated with different con-
centrations of dhSph (5 μg/mL–20 μg/mL) in the presence or absence
of 100 μMOSIP108, upon treatment with 2 mM Cu or control. No signif-
icant effect on yeast survival was observedwith dhSph alone (Fig. 6).We
observed a signiﬁcant increase in survival upon incubationwith OSIP108
in the presence of 2 mM Cu, which was completely abolished in the
presence of 20 μg/mL dhSph. A lower dhSph dose (5 μg/mL) partially
abolished the protective effect of OSIP108, indicating a dose-dependent
effect.
Our data suggest that exogenous dhSph addition abolishes the pro-
tective effect of OSIP108 on Cu-induced cell death in a dose depen-
dent manner, without affecting yeast viability when administered
without OSIP108. Besides being incorporated into sphingolipids
[50], the exogenously added dhSph could also interfere with
the signaling function described for endogenous dhSph [51,52].
Whether OSIP108 only inhibits 3-ketodihydrosphingosine reduc-
tase or also blocks sphingolipid-mediated signaling needs to be
studied further.4. Conclusions and perspectives
We show here that the A. thaliana-derived peptide OSIP108, earlier
selected based on its oxidative stress protectant activity [13], also pro-
tects yeast and human HepG2 cells against Cu-induced toxicity, which
could further be attributed to its anti-apoptotic activity potentially me-
diated by an effect on sphingolipid homeostasis. Speciﬁcally regarding
its protective effect on HepG2 cells, OSIP108-based therapies could
thus be considered as potential new approaches in the treatment of
human diseases related to Cu toxicity such as WD. In this context it is
worth mentioning that the natural occurrence of OSIP108 seems to be
restricted to certain Arabidopsis species (Dr. Aminael Sanchez-
Rodriguez, CMPG, KU Leuven, personal communication). Moreover, a
BLASTP similarity search using the OSIP108 amino acid sequence via
PepBank did not yield any signiﬁcant hits, indicating that no OSIP108
homologues in other organisms, including lower eukaryotes (e.g.
yeast) as well as higher eukaryotes (humans), are present. Hence,
using OSIP108 as an anti-apoptotic compound can only be achieved
via exogenous application. In light of a putative application of OSIP108
as a drug for human pathologies linked to excessive apoptosis, the use
of small peptides poses several advantages over chemical molecules,
such as high speciﬁcity and low toxicity proﬁle [53]. On the other side,
their low oral bioavailability during therapeutic application, due to e.g.
enzymatic degradation in the stomach and short plasma half-life [54,
55], can be problematic. However an array of approaches currently ex-
ists to improve the pharmacological properties of peptides [56,57]. For
instance, oral insulin formulations already show promising results as
treatment of diabetes type 1 [58] and nasal administrations of
peptides such as the polypeptide hormone calcitonin [59] have been
successfully tested in clinical trials. Hence, further preclinical and clini-
cal development of OSIP108 as a novel therapy for diseases related to
excessive apoptosis such as WD or some neurodegenerative diseases
will require considerable efforts in the development of adequate
OSIP108 formulations.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.03.004.Acknowledgements
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